Infantile Spasms Therapeutics Market By Drug Type (Corticosteroids, Adrenocorticotropic Hormones (ACTH) , Antiepileptic Drugs (AEDs) , Others) , By Route of Administration (Oral, Parenteral) By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Infantile Spasms Therapeutics Market
The infantile spasms therapeutics market was valued at $162.0 million in 2023 and is projected to reach $223.4 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.
The infantile spasms therapeutics market focuses on the treatment of infantile spasms, which is a rare, severe form of epilepsy that occurs in infants between the age of 3 and 12 months. The primary treatment approaches comprise combinations of hormonal therapies, antiepileptic drugs (AEDs), and dietary interventions. Surgical interventions are considered during cases of intractable infantile spasms.
The growth of the infantile spasms therapeutics market is significantly driven by increase in awareness regarding the prevalence of neurological disorders and improvement in diagnostic capabilities. In addition, innovations in drug discovery and development have enhanced the potential of therapeutics, thereby augmenting the growth of the market. A prominent trend poised to dominate the market is the application of gene therapy & precision medicine to enhance the efficacy of treatment and improve patient outcomes. The incorporation of unique anatomical and genetic attributes of each patient via these ingenious methods is expected to reduce the occurrence of spasms in infants.
However, the high costs of therapeutics and potential side effects of different drugs deter several individuals from undergoing the treatment, restraining the growth of the infantile spasms therapeutics market. Moreover, challenges pertaining to diagnosis at early stages hamper the market growth notably. On the contrary, upsurge in funding & investments by governments or associated institutions is projected to fuel explorations in the field of infantile spasms therapeutics and present lucrative opportunities for the expansion of the market. For instance, CURE Epilepsy—an American non-profit research organization—awarded funds to Dr. David Auerbach at the Upstate Medical University in New York on December 2023 to investigate the role of cardiac biomarkers in epilepsy.
Segment Review
The infantile spasms therapeutics market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is divided into corticosteroids, adrenocorticotropic hormones (ACTH), antiepileptic drugs (AEDs), and others. Depending on route of administration, it is bifurcated into oral and parenteral. By distribution channel, it is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug type, the antiepileptic drugs (AEDs) segment is expected to dominate the market during the forecast period.
Depending on route of administration, the parenteral segment is projected to garner a high market share by 2033.
By distribution channel, the drug stores & retail pharmacies segment is anticipated to acquire a high share of the market throughout the forecast period.
Region wise, North America is predicted to be the highest revenue generator by 2033.
Competition Analysis
The major players in the global infantile spasms therapeutics market include Mallinckrodt Pharmaceuticals, H. Lundbeck A/S, Pfizer Inc., UCB Pharma S.A., Jazz Pharmaceuticals, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and AbbVie Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Key Market Segments
By Drug Type
Corticosteroids
Adrenocorticotropic Hormones (ACTH)
Antiepileptic Drugs (AEDs)
Others
By Route Of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Mallinckrodt Pharmaceuticals
H. Lundbeck A/S
Pfizer Inc.
UCB Pharma S.A.
Jazz Pharmaceuticals, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Viatris Inc.
AbbVie Inc.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Type
- 4.2. Corticosteroids
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Adrenocorticotropic Hormones (ACTH)
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Antiepileptic Drugs (AEDs)
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Others
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- CHAPTER 5: INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Route Of Administration
- 5.2. Oral
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Parenteral
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Drug Stores And Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Providers
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: INFANTILE SPASMS THERAPEUTICS MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug Type
- 7.2.3. Market Size and Forecast, By Route Of Administration
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Infantile Spasms Therapeutics Market
- 7.2.6.1. Market Size and Forecast, By Drug Type
- 7.2.6.2. Market Size and Forecast, By Route Of Administration
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Infantile Spasms Therapeutics Market
- 7.2.7.1. Market Size and Forecast, By Drug Type
- 7.2.7.2. Market Size and Forecast, By Route Of Administration
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Infantile Spasms Therapeutics Market
- 7.2.8.1. Market Size and Forecast, By Drug Type
- 7.2.8.2. Market Size and Forecast, By Route Of Administration
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug Type
- 7.3.3. Market Size and Forecast, By Route Of Administration
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Infantile Spasms Therapeutics Market
- 7.3.6.1. Market Size and Forecast, By Drug Type
- 7.3.6.2. Market Size and Forecast, By Route Of Administration
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Infantile Spasms Therapeutics Market
- 7.3.7.1. Market Size and Forecast, By Drug Type
- 7.3.7.2. Market Size and Forecast, By Route Of Administration
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Infantile Spasms Therapeutics Market
- 7.3.8.1. Market Size and Forecast, By Drug Type
- 7.3.8.2. Market Size and Forecast, By Route Of Administration
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Infantile Spasms Therapeutics Market
- 7.3.9.1. Market Size and Forecast, By Drug Type
- 7.3.9.2. Market Size and Forecast, By Route Of Administration
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Infantile Spasms Therapeutics Market
- 7.3.10.1. Market Size and Forecast, By Drug Type
- 7.3.10.2. Market Size and Forecast, By Route Of Administration
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Infantile Spasms Therapeutics Market
- 7.3.11.1. Market Size and Forecast, By Drug Type
- 7.3.11.2. Market Size and Forecast, By Route Of Administration
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug Type
- 7.4.3. Market Size and Forecast, By Route Of Administration
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Infantile Spasms Therapeutics Market
- 7.4.6.1. Market Size and Forecast, By Drug Type
- 7.4.6.2. Market Size and Forecast, By Route Of Administration
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Infantile Spasms Therapeutics Market
- 7.4.7.1. Market Size and Forecast, By Drug Type
- 7.4.7.2. Market Size and Forecast, By Route Of Administration
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Infantile Spasms Therapeutics Market
- 7.4.8.1. Market Size and Forecast, By Drug Type
- 7.4.8.2. Market Size and Forecast, By Route Of Administration
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Infantile Spasms Therapeutics Market
- 7.4.9.1. Market Size and Forecast, By Drug Type
- 7.4.9.2. Market Size and Forecast, By Route Of Administration
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Infantile Spasms Therapeutics Market
- 7.4.10.1. Market Size and Forecast, By Drug Type
- 7.4.10.2. Market Size and Forecast, By Route Of Administration
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Infantile Spasms Therapeutics Market
- 7.4.11.1. Market Size and Forecast, By Drug Type
- 7.4.11.2. Market Size and Forecast, By Route Of Administration
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug Type
- 7.5.3. Market Size and Forecast, By Route Of Administration
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Infantile Spasms Therapeutics Market
- 7.5.6.1. Market Size and Forecast, By Drug Type
- 7.5.6.2. Market Size and Forecast, By Route Of Administration
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Infantile Spasms Therapeutics Market
- 7.5.7.1. Market Size and Forecast, By Drug Type
- 7.5.7.2. Market Size and Forecast, By Route Of Administration
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Infantile Spasms Therapeutics Market
- 7.5.8.1. Market Size and Forecast, By Drug Type
- 7.5.8.2. Market Size and Forecast, By Route Of Administration
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Infantile Spasms Therapeutics Market
- 7.5.9.1. Market Size and Forecast, By Drug Type
- 7.5.9.2. Market Size and Forecast, By Route Of Administration
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Mallinckrodt Pharmaceuticals
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. H. Lundbeck A/S
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. UCB Pharma S.A.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Jazz Pharmaceuticals, Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Novartis AG
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Teva Pharmaceutical Industries Ltd.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Sun Pharmaceutical Industries Ltd.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Viatris Inc.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. AbbVie Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 2. INFANTILE SPASMS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 3. INFANTILE SPASMS THERAPEUTICS MARKET FOR ADRENOCORTICOTROPIC HORMONES (ACTH), BY REGION, 2024 - 2033 ($MILLION)
- TABLE 4. INFANTILE SPASMS THERAPEUTICS MARKET FOR ANTIEPILEPTIC DRUGS (AEDS), BY REGION, 2024 - 2033 ($MILLION)
- TABLE 5. INFANTILE SPASMS THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 7. INFANTILE SPASMS THERAPEUTICS MARKET FOR ORAL, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 8. INFANTILE SPASMS THERAPEUTICS MARKET FOR PARENTERAL, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 10. INFANTILE SPASMS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 11. INFANTILE SPASMS THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 12. INFANTILE SPASMS THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 13. INFANTILE SPASMS THERAPEUTICS MARKET, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 14. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 15. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 16. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 17. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 18. U.S. INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 19. U.S. INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 20. U.S. INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 21. CANADA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 22. CANADA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 23. CANADA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 24. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 25. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 26. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 27. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 28. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 29. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 30. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 31. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 32. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 33. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 34. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 35. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 36. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 37. ITALY INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 38. ITALY INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 39. ITALY INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 40. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 41. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 42. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 43. UK INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 44. UK INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 45. UK INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 46. REST OF EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 47. REST OF EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 48. REST OF EUROPE INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 49. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 50. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 51. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 52. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 53. CHINA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 54. CHINA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 55. CHINA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 56. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 57. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 58. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 59. INDIA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 60. INDIA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 61. INDIA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 62. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 63. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 64. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 65. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 66. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 67. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 71. LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 72. LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 73. LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 74. LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 75. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 76. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 77. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 78. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 79. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 80. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 81. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 82. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 83. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 84. REST OF LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY DRUG TYPE, 2024 - 2033 ($MILLION)
- TABLE 85. REST OF LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($MILLION)
- TABLE 86. REST OF LAMEA INFANTILE SPASMS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 87. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 88. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 89. MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 90. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 91. MALLINCKRODT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 92. H. LUNDBECK A/S: KEY EXECUTIVES
- TABLE 93. H. LUNDBECK A/S: COMPANY SNAPSHOT
- TABLE 94. H. LUNDBECK A/S: OPERATING SEGMENTS
- TABLE 95. H. LUNDBECK A/S: PRODUCT PORTFOLIO
- TABLE 96. H. LUNDBECK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 97. PFIZER INC.: KEY EXECUTIVES
- TABLE 98. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 99. PFIZER INC.: OPERATING SEGMENTS
- TABLE 100. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 101. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 102. UCB PHARMA S.A.: KEY EXECUTIVES
- TABLE 103. UCB PHARMA S.A.: COMPANY SNAPSHOT
- TABLE 104. UCB PHARMA S.A.: OPERATING SEGMENTS
- TABLE 105. UCB PHARMA S.A.: PRODUCT PORTFOLIO
- TABLE 106. UCB PHARMA S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 107. JAZZ PHARMACEUTICALS, INC.: KEY EXECUTIVES
- TABLE 108. JAZZ PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 109. JAZZ PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 110. JAZZ PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 111. JAZZ PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 112. NOVARTIS AG: KEY EXECUTIVES
- TABLE 113. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 114. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 115. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 116. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 122. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 123. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 124. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 125. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 126. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 127. VIATRIS INC.: KEY EXECUTIVES
- TABLE 128. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 129. VIATRIS INC.: OPERATING SEGMENTS
- TABLE 130. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 131. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 132. ABBVIE INC.: KEY EXECUTIVES
- TABLE 133. ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 134. ABBVIE INC.: OPERATING SEGMENTS
- TABLE 135. ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 136. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF INFANTILE SPASMS THERAPEUTICS MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN INFANTILE SPASMS THERAPEUTICS MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALINFANTILE SPASMS THERAPEUTICS MARKET
- FIGURE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION, BY DRUG TYPE
- FIGURE 11. INFANTILE SPASMS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 12. INFANTILE SPASMS THERAPEUTICS MARKET FOR ADRENOCORTICOTROPIC HORMONES (ACTH), BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 13. INFANTILE SPASMS THERAPEUTICS MARKET FOR ANTIEPILEPTIC DRUGS (AEDS), BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 14. INFANTILE SPASMS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 15. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
- FIGURE 16. INFANTILE SPASMS THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 17. INFANTILE SPASMS THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 18. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 19. INFANTILE SPASMS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 20. INFANTILE SPASMS THERAPEUTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 21. INFANTILE SPASMS THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 26. COMPETITIVE DASHBOARD
- FIGURE 27. COMPETITIVE HEATMAP: INFANTILE SPASMS THERAPEUTICS MARKET
- FIGURE 28. TOP PLAYER POSITIONING, 2023
- FIGURE 29. MALLINCKRODT PHARMACEUTICALS: NET SALES, 2021-2023 ($MILLION)
- FIGURE 30. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 31. MALLINCKRODT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 32. H. LUNDBECK A/S: NET SALES, 2021-2023 ($MILLION)
- FIGURE 33. H. LUNDBECK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 34. H. LUNDBECK A/S: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 35. PFIZER INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 36. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 37. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 38. UCB PHARMA S.A.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 39. UCB PHARMA S.A.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 40. UCB PHARMA S.A.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 41. JAZZ PHARMACEUTICALS, INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 42. JAZZ PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 43. JAZZ PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 44. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
- FIGURE 45. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 46. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 50. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 51. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 52. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 53. VIATRIS INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 54. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 55. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 56. ABBVIE INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 57. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 58. ABBVIE INC.: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook